InvIOs GmbH revealed today that it has launched patient enrollment for a Phase 1b trial of its innovative autologous cell therapy, APN401, focusing on solid tumor patients.

The European Union Commission has approved Pfizer's ABRYSVO™ to protect infants and the elderly from Respiratory Syncytial Virus infections via maternal vaccination.

RLYB116, a potential long-acting solution, is a subcutaneously administered C5 inhibitor which is currently being developed for managing patients with complement-mediated diseases.

Bayer’s Kerendia (finerenone)  had gained approval for usage in managing chronic kidney diseases affiliated with type 2 diabetes two summers ago.

Stallerges Greer has disclosed a contract with Nestle regarding the use of Palforzia ® A global agreement to treat peanut allergies.

Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors.

Comanche Biopharma grants Fast Track Status by FDA for CBP-4888, aimed at treating sFlt-1 induced early-onset preeclampsia

Abata Therapeutics reveals the second development candidate, ABA-201, designed for the management of Type 1 Diabetes

AusperBio Therapeutics, Inc.have declared today that the FDA has sanctioned the IND application for testing of AHB-137 in clinics.

Data analysis from a sample of 822 patients reveals noticeable mepolizumab in symptomatology among Mepolizumab-treated adult asthma sufferers a year post-treatment, regardless of the existence of concomitant medical conditions.

Carisma Therapeutics's primary candidate product, CT-0508, is set to be displayed at this year's 8th annual CAR-TCR conference.

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in the development of STAT3 inhibitors, has initiated dosing of the first patients in its ongoing REVERTIPF trial.